×

Anti-TNF antibody formulations

DC
  • US 9,085,619 B2
  • Filed: 10/03/2014
  • Issued: 07/21/2015
  • Est. Priority Date: 11/30/2007
  • Status: Active Grant
First Claim
Patent Images

1. An aqueous pharmaceutical formulation consisting essentially of:

  • (a) an anti-tumor necrosis factor alpha antibody comprising a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO;

    3, a CDR2 domain comprising the amino acid sequence of SEQ ID NO;

    5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO;

    7, and a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO;

    4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO;

    6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO;

    8, wherein the concentration of the antibody is 50 to 200 mg/ml; and

    (b) water.

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×